Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Adherence To The Ibrutinib 420 mg Dose Administered To Patients With Previously Treated CLL
Clinical Lymphoma, Myeloma & Leukemia (2015)
  • Jan A. Burger, University of Texas MD Anderson Cancer Center
  • Paul M. Barr, University of Rochester
  • Jennifer R. Brown, Harvard University
  • Peter Hillmen, Leeds Teaching Hospitals NHS Trust
  • Susan O'Brien, University of Texas MD Anderson Cancer Center
  • Jacqueline C. Barrientos, Cancer Institute
  • Nishitha M. Reddy, Vanderbilt University
  • Steven Coutre, Stanford University
  • Stephen P. Mulligan, Royal North Shore Hospital
  • Ulrich Jaeger, Medical University of Vienna
  • Richard R. Furman, NewYork–Presbyterian Hospital
  • Florence Cymbalista, University of Paris
  • Marco Montillo, Catholic University of the Sacred Heart
  • Claire Dearden, The Royal Marsden NHS Foundation Trust
  • Tadeusz Robak, Medical University of Łódź
  • Carol Moreno, Autonomous University of Barcelona
  • John Pagel, Cancer Institute
  • Samuel Suzuki
  • Juthamas Sukbuntherng, Celera Corporation
  • George Cole
  • Danelle F. James, University of California, San Diego
  • John C. Byrd, Ohio State University
Link
Disciplines
Publication Date
January 9, 2015
DOI
10.1016/j.clml.2015.07.053
Citation Information
Jan A. Burger, Paul M. Barr, Jennifer R. Brown, Peter Hillmen, et al.. "Adherence To The Ibrutinib 420 mg Dose Administered To Patients With Previously Treated CLL" Clinical Lymphoma, Myeloma & Leukemia Vol. 15 (2015)
Available at: http://works.bepress.com/john-pagel/79/